Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21593566 | 0.88 | ESR1 (0.36) | ESR2ESR1KDM4ENPC1SMN1; SMN2 | |
| SCHEMBL21593663 | 0.80 | NPC1 (0.43) | ESR2ESR1KDM4ENPC1CCR1 | |
| SCHEMBL7215767 | 0.74 | ESR2 (0.36) | ESR2ESR1KDM4ENPC1CCR1 | |
| SCHEMBL31601048 | 0.74 | ESR2 (0.41) | ESR2ESR1KDM4ENPC1SMN1; SMN2 | |
| SCHEMBL862238 | 0.70 | CCR1 (0.50) | KDM4ENPC1CCR1CCR5CCR8 | |
| SCHEMBL23758436 | 0.70 | GAA (0.44) | ESR2ESR1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL31600625 | 0.69 | KDM4E (0.38) | ESR2ESR1KDM4ENPC1SMN1; SMN2 | |
| SCHEMBL11332805 | 0.68 | ALDH1A1 (0.50) | KDM4ENPC1CCR1CCR5CCR8 | |
| SCHEMBL21591890 | 0.68 | SMN1; SMN2 (0.44) | KDM4ENPC1CCR1CCR5CCR8 | |
| SCHEMBL29362546 | 0.68 | SMN1; SMN2 (0.44) | KDM4ENPC1CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | disclosed |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2024-01-30 | — | — | US | disclosed |
| EP-3807278-B1 | PURINONE DERIVATIVES AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-08-31 | — | — | EP | disclosed |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | ESR2 1887/4885ESR1 2666/4885KDM4E 2288/4885 |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | ESR2 1939/4885ESR1 2245/4885KDM4E 1890/4885 |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | RECQL, PRPS1, PURB | ESR2 1887/4885ESR1 2666/4885KDM4E 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.